Emirodatamab Biosimilar Bispecific scFv–Fc Antibody (FLT3 × CD3) for Research

Cat No.: GMP-Bios-INN-1178

Anti-FLT3/CD135/FLK2 therapeutic antibody (Pre-made Emirodatamab biosimilar,Bispecific scFv-scFv-scFc) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Emirodatamab (development code AMG 427) is a bispecific antibody targeting FLT3 and CD3. It is developed by Amgen and BeiGene for acute myeloid leukemia. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1178-1mg 1mg
GMP-Bios-INN-1178-10mg 10mg
GMP-Bios-INN-1178-100mg 100mg
GMP-Bios-INN-1178-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Emirodatamab biosimilar, Bispecific scFv-scFv-scFc, Anti-FLT3/CD135/FLK2;CD3E Antibody: Anti-FLT3/CD135/FLT-3/Receptor-type tyrosine-protein kinase FLT3 therapeutic antibody
INN Name Emirodatamab
Target FLT3/CD135/FLK2;CD3E
Format Bispecific scFv-scFv-scFc
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype na;na
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Discontinued
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2022
Year Recommended 2022
Companies Amgen;BeiGene
Conditions Approved na
Conditions Active na
Conditions Discontinued Acute myeloid leukaemia
Production na
Development Tech na